Overview

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.
Collaborator:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Calcium
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin